Full factorial design assisted RP-UHPLC method development and study of stressed degradation of molnupiravir
DOI:
https://doi.org/10.22456/2527-2616.134441Keywords:
Molnupiravir, RP-UHPLC, factorial, COVID-19, degradationAbstract
To combat the SARS-CoV-2 addition of molnupiravir into the current therapeutic regimen has added new hopes. But currently, not so many analytical methods are available for analyzing molnupiravir. The current study aimed at developing a suitable and efficient RP-UHPLC method for molnupiravir capitalizing full factorial design. The optimized method involved the use of trifluoroacetic acid (0.1%): methanol at a ratio of 65:35 (%, v/v) with fortis diphenyl HPLC column (150 mm x 4.6 mm i.d. [internal diameter], 5 μm particle size). The method was found highly specific (purity index <1.5), linear (0.5-100 μg.mL-1), accurate (~100%), precise, rugged, and robust (%RSD<2). A stress degradation study exhibited that 0.1N HCl at 100˚C (±1˚C) for 2 hours caused drug degradation crossing its limit (>10%), the drug is extremely susceptible to basic hydrolysis and 0.1N NaOH at room temperature for 1 min caused 65.43% degradation, exposure in 3% H2O2 at 100˚C (±1˚C) for 1 hours caused the drug degradation over 10%, and 5 days of exposure to short wavelength UV light caused 13.16% of drug degradation. The research work successfully developed an efficient and validated method for analyzing molnupiravir in the RP-UHPLC system. Moreover, the degradation study performed will aid in adding integral information related to the stability of the drug molecule.
Downloads
Downloads
Published
Versions
- 26-03-2026 (2)
- 15-01-2024 (1)
How to Cite
Issue
Section
License
Copyright (c) 2023 Drug Analytical Research

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Copyright holder of manuscripts published is Drug Analytical Research. Authors who publish with this journal are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Licensing:
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author.





